Table S1-S6, and Figure S1-S4 from Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance

Table S1. Clinical characteristics of assessable patients; Table S2. Cox analysis for prediction of progression-free survival (PFS) and overall survival (OS) in an histo-pathlogical HER2 positive (hHER2+) cohort; Table S3. Cox analysis for prediction of PFS and OS in an histo-pathological HER2 negative (hHER2-) cohort; Table S4. Quantified variation of HER2+/triploid CTCs and its correlation to prognosis; Table S5. Quantified variation of HER2+/tetraploid CTCs and its correlation to prognosis; Table S6. Cox analysis for prediction of PFS and OS for variation of HER2+/multiploid circulating tumor cells (CTCs); Figure S1. CONSORT flow chart; Figure S2. Quantification of HER2 expression on CTCs (cHER2) in gastric cancer (GC); Figure S3. Threshold of pre-therapeutic cHER2+ CTCs for predicting OS in the hHER2+ and hHER2- cohorts of patients with GC; Figure S4. Quantitative variation of aneuploid CTCs is in accordance with variation of HER2+ CTCs in patients from pre-therapy to progression.